Autologous transplantation in DLBCL and unmet needs

Advances and unmet needs in second-line treatment of DLBCLПодробнее

Relapse in DLBCL - addressing the unmet need with brentuximab vedotinПодробнее

Improving second-line treatments in DLBCLПодробнее

Autologous Stem Cell Transplant Should Remain Standard of Care for Certain DLBCL PatientsПодробнее

What are the challenges of integrating therapy around autologous transplantation?Подробнее

CAR-T therapy versus autoSCT in DLBCLПодробнее

CAR-T therapy vs autologous transplantation in R/R DLBCLПодробнее

Unmet needs in second-line DLBCL and challenges in this spaceПодробнее

R/R DLBCL: Transplant Eligibility and R-CHOPПодробнее

Can we offer a curative treatment to transplant-ineligible R/R DLBCL patients?Подробнее

Dr. Pagel on Challenges With ASCT in Relapsed/Refractory DLBCLПодробнее

Selecting and risk stratifying patients with DLBCL for ASCTПодробнее

Hodgkin lymphoma: when autologous transplant is unsuccessfulПодробнее

Will CAR-T therapy take over from autologous transplantation in lymphoma?Подробнее

Updates in the DLBCL treatment landscapeПодробнее

Can CAR-T cells replace ASCT in DLBCL?Подробнее

The role of stem cell transplantation in the era of targeted therapies in DLBCL and MCLПодробнее

Areas of unmet need for DLBCL: primary refractory disease and double-hit lymphomaПодробнее

Part 3 - Update on stem cell transplant in Lymphoma - Dr Hari Parameswaran, USAПодробнее